Computational Simulation of the Bioactivity of Selected Compounds Derived From the Sapium and Salvias Genera as Anticancer Agents
Abstract
The investigation into the anticancer properties of plant extracts, which are known to be effective therapeutic agents with minimal side effects, is gaining significant traction. The current study examined the bioactive compounds extracted from Sapium ellipticum and Salvia miltiorrhiza Bunge. Salvianolic acid (Sal B), ellagic acid (EA), [20-3H]-12-deoxyphorbol-13-isobutyrate ([3H] DPB), and [20-3H] phorbol-12, 13-dibutyrate ([3H] PDBu) have all been analyzed in vitro and in silico. Based on the molecular docking simulations, Sal B targeted DNA lyase, topoisomerase II alpha, and mTOR, with docking scores of -9.5, -6.9, and -7.9 kcal/mol, respectively. The docking scores of these compounds were comparable with those of EA, which had a docking score of -8.7, -6.5, and -7.6 kcal/mol when targeting DNA lyase, topoisomerase II alpha, and mTOR, respectively. Remarkably, Sal B (-9.0 kcal/mol), EA (-7.6 kcal/mol), [3H] PDBu (-8.7 kcal/mol), and [3H] DPB (-7.1 kcal/mol) showed weaker binding affinities to the mTOR kinase enzyme compared with rapamycin (-11.2 kcal/mol). With an IC50 of 11.6 μM, Sal B demonstrated remarkable efficacy and was almost as effective as the common inhibitor rapamycin (IC50 of 5.2 μM). With an IC50 of 21.9 μM, EA demonstrated a mild but similar inhibition. The assay and docking results were validated by the root mean square deviation (RMSD) plots of Sal B and EA, which demonstrated that they are both kinetically stable. The results of this study present a…
Read the paper
Related studies
- Chaos and quantum thermalization
- The Dalton quantum chemistry program system
- Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study
- Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes
- Stable adiabatic quantum batteries
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.